Managing Director, GBS Ventures
| Role | Organisation | Sources |
|---|---|---|
| Managing Director (former) | GBS Venture Partners Ltd. | GBS Ventures |
| Managing Director | GBS Ventures | GBS Ventures (Mon 2 Nov 2020), GBS Ventures (Mon 3 Aug 2020), GBS Ventures (Fri 28 Sep 2018), GBS Ventures (Tue 30 Jun 2015) |
Stories naming Brigitte Smith. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
GBS Ventures marks its fourth FDA drug approval as Hatchtech's head lice treatment Xeglyze clears the regulator, recalling earlier wins behind Picato, Synribo and Aridol with Australian biotech firms.
GBS Ventures reports Novartis has agreed to acquire chronic-pain drug developer Spinifex Pharmaceuticals for US$200 million upfront plus milestones, recalling the company's 2005, 2008 and 2014 venture rounds and its Australian investors.
Also GBS Ventures·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·novartis.com·clinicalleader.com·Brandon Capital portfolio·Startup Daily·Startup Daily·Startup Daily·anthillonline.com·@AuManufacturing·materresearch.org.au·Business News Australia
GBS Ventures announces it has fully wound down its 1998 biotech fund with returns in the top quartile of US peers, recalling portfolio listings, Dynamic Hearing's sale to Wolfson, and its $122.5m fourth fund.
GBS Venture Partners closed its third life science fund at $145 million, exceeding its $120 million target, with backing from returning and new Australian institutional investors.